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We studied the association between dietary folate and speciﬁc
K-ras mutations in colon and rectal cancer in The Netherlands
Cohort Study on diet and cancer. After 7.3 years of follow-up, 448
colon and 160 rectal cancer patients and 3,048 sub-cohort mem-
bers (55–69 years at baseline) were available for data analyses.
Mutation analysis of the K-ras gene was carried out on all archival
adenocarcinoma specimens. Case–cohort analyses were used to
compute adjusted incidence rate ratios (RR) and 95% conﬁdence
intervals (CI) for colon and rectal cancer overall and for K-ras
mutation status subgroups according to 100 g/day increased
intake in dietary folate. Dietary folate intake was not signiﬁcantly
associated with colon cancer risk for men or women, neither
overall nor with K-ras mutation status. For rectal cancer, folate
intake was associated with a decreased disease risk in men and was
most pronounced for K-ras mutated tumors, whereas an increased
association was observed for women. Regarding the K-ras muta-
tion status in women, an increased association was observed for
both wild-type and mutated K-ras tumors. Speciﬁcally, folate in-
take was associated with an increased risk of G>T and G>C
transversions in rectal tumors (RR  2.69, 95% CI  1.43–5.09),
but inversely associated with G>A transitions (RR  0.08, 95%
CI 0.01–0.53). Our data suggest that the effect of folate on rectal
cancer risk is different for men and women and depends on the
K-ras mutation status of the tumor.
© 2004 Wiley-Liss, Inc.
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To date, results from epidemiological studies1–4 generally show
an inverse association between dietary folate and the risk of
colorectal cancer. Associations may be different, however, for men
vs. women and for colon vs. rectum.4,5 In addition, the results from
most animal studies support the epidemiological data, but results
were not always consistent.1,2
Folate plays an important role in the one-carbon metabolism, a
series of interrelated biochemical reactions involved in DNA syn-
thesis and methylation of DNA, RNA and proteins6 in animals and
humans. Two pathways have been described linking a low folate
status to colon and rectum carcinogenesis.6,7 First, a deﬁcient
intracellular form of folate, 5,10-methylenetetrahydrofolate (5,10-
methyleneTHF), leads to a decreased availability of methyl groups
for uracil that may result in less available thymine. Eventually, the
increased uracil incorporation in DNA may lead to DNA strand
breaks and chromosome instability. Second, sub-optimal folate
status may result in global DNA hypomethylation and regional
hypermethylation in gene promoters that interferes with gene
expression and can impair DNA repair.8,9 DNA strand breaks,
global DNA hypomethylation and regional promoter hypermeth-
ylation are common events in colon cancer.
The association between folate and colorectal cancer was eval-
uated earlier in The Netherlands Cohort Study on diet and cancer
(NLCS), based on 7.3 years of follow-up.3,10 In this study,3 the
association between high folate intake and colon cancer tended to
be inverse for men and women after the exclusion of the ﬁrst year
of follow-up, but did not reach statistical signiﬁcance. For rectal
cancer, folate was inversely associated with the disease risk in
men, although borderline signiﬁcant, but not in women. Evaluating
these ﬁndings, it would be interesting to study the association
between dietary folate and CRC when speciﬁc mutations in genes
involved in colorectal carcinogenesis are taken into account.
The oncogenic activation of K-ras by mutations is a genetic
alteration that occurs in adenomas (10%) as well as in carcinomas
(40%) in colon and rectal cancer. Activating mutations are mainly
found in codons 12 and 13.11–14 The types of point mutations
observed most frequently are GA transitions, and GT and
GC transversions.14–16 Possibly, the GA transitions observed
frequently in the K-ras gene are a result of impaired promoter
methylation of the DNA-repair gene O6-methylguanine DNA
methyltransferase (MGMT)9 that could, in part, be due to a low
folate status.10
Only 3 epidemiological studies report on the association be-
tween folate intake and K-ras mutation status in colon (rectal)
tumors17,18 and in colorectal adenomas7 with varying results. It is
difﬁcult to compare the results from different studies, however,
due to differences in case groups and reference groups. In our
current study, the association between dietary folate intake and the
risk of speciﬁc point mutations in the K-ras oncogene in patients
with colon and rectal cancer were studied for men and women
within the framework of the NLCS.
Material and methods
Study population
The participants in our study are incident colon and rectal cancer
cases and subcohort members from the NLCS, which has been
described in detail elsewhere.19 The study was initiated in 1986
and includes 58,279 men and 62,573 women, 55–69 years of age
at baseline, who originated from 204 Dutch municipalities with
computerized population registries. A self-administered question-
naire on diet and other risk factors for cancer was completed at
baseline. The entire cohort is being monitored for cancer occur-
rence by annual record linkage to the Netherlands Cancer Registry
(NCR; 9 cancer registries in The Netherlands) and to PALGA, a
nationwide network and registry of histo- and cytopathology re-
ports (www.palga.nl).20 In the municipalities included in the
NLCS, the NCR and PALGA have nearly 100% coverage since the
start of the study.21–24 PALGA also provides necessary informa-
tion on the identiﬁcation of the pathology laboratory location of
the storage of parafﬁn-embedded blocks of the eligible CRC
patients. Accumulation of person-time in the cohort has been
estimated through biennial vital status follow-up of a subcohort of
3,500 men and women who were randomly selected after baseline
exposure measurement. Cases with prevalent cancer other than
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non-melanoma skin cancer were excluded from the subcohort,
which left 3,346 men and women for analysis.
The ﬁrst 2.3 years of follow-up were excluded because of
possible preclinical disease affecting exposure status and because
of incomplete coverage of PALGA alone in some of the munici-
palities included in the NLCS. Within this period, 83 subcohort
members were either deceased or diagnosed with cancer other than
non-melanoma skin cancer, leaving 3,263 men and women for
analysis. From 1989–1994, 929 incident cases with histologically
conﬁrmed CRC were observed of whom 819 could also be linked
to a PALGA report of the lesion. The PALGA database was used
to identify and locate tumor tissue in Dutch pathology laboratories.
CRC was classiﬁed according to site as follows: colon i.e., cecum
through sigmoid colon (ICD-O-1 codes: 153.0, 153.1, 153.2,
153.3, 153.4, 153.5, 153.6, 153.7, 153.8, 153.9), rectosigmoid
(ICD-O-1 code 154.0) and rectum (ICD-O-1 code 154.1). Infor-
mation about age at baseline, gender and family history of CRC (at
baseline) was retrieved from the NLCS database.
Tissue samples
Tumor material of all CRC patients was collected after approval
by the Medical Ethics Committees (MEC) of Maastricht Univer-
sity, the NCR and PALGA.14 Subsequently, all pathology labora-
tories in The Netherlands agreed to make relevant tissue samples
available upon request from PALGA. Tissue samples of the 819
cases present in 54 pathology laboratories throughout The Neth-
erlands, were collected between August 1999 and December 2001.
For 43 (5%) untraceable tumor tissue specimens and 39 (5%)
specimens with insufﬁcient CRC tumor material, K-ras mutation
status could not be determined. Tumor material from 737 incident
colorectal adenocarcinoma cases was available of whom 476 were
colon cancer cases, 85 were rectosigmoid cancer cases and 176
were rectal cancer cases. Statistical analyses were carried out
separately for colon and rectal cancer as differences in the etiology
of colon and rectal cancer have been reported.25 Because the
rectosigmoid can be considered as a clinically applied term rather
than an anatomically deﬁned transitional zone between the colon
and rectum, patients with a rectosigmoid tumor were excluded
from data-analyses. Moreover, the number of patients with a
rectosigmoid tumor was too small for adequate stratiﬁed analy-
ses.14
Detection of K-ras mutations
Mutation analysis of the exon 1 fragment of the K-ras oncogene,
spanning codons 8–29, was carried out on archival colorectal
adenocarcinoma specimens of all 737 CRC patients using macro-
dissection, nested PCR and direct sequencing of puriﬁed frag-
ments, which has been described in detail elsewhere.14
Food frequency questionnaire
The dietary section of the questionnaire was a 150-item semi-
quantitative food frequency questionnaire, which concentrated on
habitual consumption of food and beverages during the year pre-
ceding the start of the study. Daily mean nutrient intakes were
calculated by cumulating the multiplied frequencies and portion
sizes of all food items with their tabulated nutrient contents from
the Dutch food composition table.26 The questionnaire was vali-
dated against a 9-day diet record.27 Questionnaire data were key-
entered twice and processed for all incident cases in the cohort and
for all subcohort members in a manner blinded with respect to
case/subcohort status. This was done to minimize observer bias in
coding and interpretation of the data.
Folate data were derived from a validated liquid chromatogra-
phy trienzyme method28 used to analyze the 125 most important
dutch foods contributing to folate intake.29 The mean daily intakes
of all other relevant nutrients were calculated using the comput-
erized Dutch Food Composition Table (NEVO Table, 1986).26 For
data-analyses, an increment of 100 g/day increase in folate intake
for men and women was computed.
For 257 subjects (28 incident colon adenocarcinoma cases, 16
incident rectal adenocarcinoma cases and 215 subcohort members,
two subcohort members were also colon or rectal cancer cases),
dietary data were incomplete or inconsistent, and they were ex-
cluded from the analyses. These subjects either (i) left 60 or more
(of 150) questionnaire items blank and ate fewer than 35 items at
least once per month or (ii) left one or more item blocks (groups
of items, e.g., beverages) blank. Additional details are given else-
where.27 Hence, 608 colon (242 men and 206 women) and rectal
cases (104 men and 56 women) and 3,048 subcohort members
(1,475 men and 1,573 women) were available for data-analyses.
Daily intake of dietary ﬁbre (g/day), vitamin B2 (mg/day),
vitamin B6 (mg/day), vitamin C (g/day), iron (mg/day), alcohol
(g/day), fresh meat (g/day), and total energy (kcal/day) and age at
baseline (years), Body Mass Index (BMI; kg/m2), physical activity
(30 min/day, 30–60 min/day, 60–90 min/day, 90 min/day),
family history of CRC (yes/no) and smoking status (never/ex/
current) were regarded as potential confounders.
Statistical analysis
Analyses were conducted for men and women separately. The
overall frequency of K-ras mutations as well as the type of muta-
tion were computed for all colon and rectal cancer cases as
described elsewhere.14 Mean values of the continuous variables
age at baseline (years), intake of total folate, dietary ﬁber, alcohol,
fresh meat, vegetables and total energy and BMI were evaluated
for subcohort members and colon and rectal cancer cases with
wild-type and mutated K-ras gene. Differences in mean values of
the continuous variables between patients with wild-type and
mutated K-ras gene were tested with the Student’s t-test or the
Mann-Whitney U-test if the variables were not distributed nor-
mally. Distributions of the categorical variables family history of
CRC, smoking status and physical activity were evaluated for
subcohort members and colon and rectal cancer patients with
wild-type and mutated K-ras gene and tested for differences be-
tween patient groups with the 2 test. The statistical software
package SPSS (version 9) was used for these analyses.
Age-adjusted and multivariate-adjusted incidence rate ratios
(RR) and their 95% conﬁdence intervals (CI) for colon and rectal
cancer risk were calculated for men and women separately, using
Cox proportional hazards regression models with the STATA
statistical software package (intercooled STATA, version 7). Stan-
dard errors were estimated using the robust Huber-White sandwich
estimator to account for additional variance introduced by sam-
pling from the cohort. This method is equivalent to the variance-
covariance estimator as presented by Barlow.30 The proportional
hazards assumption was tested using the scaled Schoenfeld resid-
uals.31 Those variables that were found to contribute substantially
(p  0.10) to the multivariate model for colon or rectal cancer
(age, smoking, BMI, total fresh meat consumption, and intake of
iron and vitamin C) were included as covariates in all multivariate
analyses. Additional adjustment for dietary ﬁber and energy intake
was carried out, in line with the previous report on folate and
overall colon and rectal cancer risk in the Netherlands Cohort
Study.3 The person-years at risk, estimated from the subcohort,
were used in the analyses.
To date, foods are not fortiﬁed with folic acid in The Nether-
lands. For the time being, an intake of 200 g of vegetables and 2
pieces of fruit daily is recommended. This is approximately twice
the amount of fruit and vegetables found to be consumed in the
Dutch National Food Consumption Survey (DNFCS) carried out in
1992. The fruit and vegetable intake accounts for approximately 50
g folate.29 We calculated RR according to an increase in intake
of 100 g/day of folate. Approximately twice this additional
amount would be necessary to reach the United States recom-
mended daily allowance of 400 g/day in the majority of the men
and women of this cohort.
825FOLATE AND K-RAS IN COLORECTAL CANCER
Results
The overall frequency and spectrum of mutations in the K-ras
gene have been presented in detail elsewhere.14 In brief, 227
mutations was found in 218 of 608 (36%) colon and rectal cancer
patients. The mutations observed most frequently are the GA
transitions (54%), GT transversions (33%) and GC transver-
sions (7%). The observed frequencies of the mutations in this
series of patients are similar to the frequencies of the 737 colo-
rectal cancer cases (including the rectosigmoid) for whom K-ras
status was determined.14
Table I shows the folate intake and other baseline characteristics
for colon cancer cases and subcohort members, separately for men
and women. The mean age of the subcohort members was 61.3
years for men and 61.4 years for women. Overall, colon cancer
cases were older than the subcohort members. Colon cancer pa-
tients with a mutated K-ras gene were signiﬁcantly older than the
patients with a wild-type K-ras gene (p-values 0.04 and 0.06 for
men and women, respectively). Dietary folate intake was higher
among subcohort members as compared to the different colon
cancer subgroups. No statistically signiﬁcant differences for other
(dietary) factors were observed for colon cancer cases without and
with a K-ras mutation in men and women as presented in Table I.
For rectal cancer cases and subcohort members, the mean folate
intake and other baseline characteristics are presented in Table II.
Rectal cancer patients were older than the subcohort members.
Dietary folate intake among subcohort members and the different
rectal cancer subgroups was similar. Women with a mutated K-ras
rectal tumor were more often ex-smoker as compared to women
with a wild-type K-ras rectal tumor and subcohort members. No
statistically signiﬁcant differences for other (dietary) factors were
observed for rectal cancer cases without and with a K-ras mutation
in men and women as presented in Table II.
For colon cancer, associations between folate intake and risk of
disease, as well as K-ras mutation status are presented for men and
women in Table III. No signiﬁcant association was observed
between dietary folate and overall colon cancer risk or with the
K-ras mutation status after adjustment for age, BMI, smoking,
alcohol, fresh meat, energy intake and family history of colorectal
cancer, iron intake, vitamin C intake and dietary ﬁbre.
For rectal cancer, associations between folate intake and risk of
disease overall, as well as K-ras mutation status are presented for
men and women in Table IV. A signiﬁcant, inverse association
was observed between folate and overall rectal cancer risk in men
(RR  0.58, 95% CI  0.36–0.93), as well as with a K-ras
mutation in the tumor (RR  0.40, 95% CI  0.17–0.89). The
association was strongest for GT or GC transversions in the
K-ras gene (RR  0.19, 95% CI  0.03–1.07). For women, a
signiﬁcant positive association was observed between folate and
overall rectal cancer risk (RR  1.85, 95% CI  1.13–3.02) and
this association was observed for rectal tumors without and with a
K-ras oncogene mutation (RR  1.94, 95% CI  1.03–3.66 and
1.83, 95% CI 0.91–3.68, respectively). After taking into account
the speciﬁc point mutations in the K-ras gene, an increased risk
was observed for rectal tumors harboring GT or GC transver-
sions (RR  2.69, 95% CI  1.43–5.09). A signiﬁcant inverse
association was observed between folate and GA transitions
(RR  0.08, 95% CI  0.01–0.53).
Discussion
In a large cohort with 448 incident colon cancer patients and 160
incident rectal cancer patients, no signiﬁcant associations were
observed between folate intake and the risk of colon cancer in men
and women, neither overall nor after the K-ras mutation status was
taken into account. For men, a protective effect was observed for
folate and rectal cancer risk, overall and most pronounced, with
K-ras mutated tumors. For women, however, a positive association
was observed between folate and rectal cancer risk, overall and
also when the K-ras mutation status was taken into account.
Regarding the speciﬁc point mutations in the K-ras gene of rectal
tumors in women, dietary folate was positively associated with
GT or GC transversions, however, inversely associated with
GA transitions.
The current cohort study on folate intake and speciﬁc K-ras
mutations is, to our knowledge, the only prospective study carried
out to date taking into account the K-ras mutation status. The
prospective design of our study and high completeness of fol-
low-up of cancer incidence and subcohort make information and
selection bias unlikely. In addition, as a result of the exclusion of
the ﬁrst 2.3 years of follow-up, the chance of information bias due
to potential preclinical colorectal cancer is minimal.
Although several epidemiological studies have been conducted on
dietary factors and K-ras mutations in colon and rectal cancer, only 3
have reported on folate intake, i.e., one large case-control study with
colon cancer patients,17 one case-control study with colon and rectal
cancer patients18 and one cross-sectional case–case study with colo-
rectal adenoma patients.7 Slattery et al.17 observed a statistically
signiﬁcant, inverse association between dietary folate intake and the
risk of colon tumors with a wild-type K-ras gene (OR for the lowest
vs. the highest tertile of intake 1.4, 95% CI 1.1–1.8; ptrend 0.01).
In another smaller case-control study with colon and rectal cancer
patients, no statistical differences in dietary folate intake as observed
between cases with a K-ras mutation compared to cases with a
wild-type K-ras.18 Therefore, case–control analyses regarding dietary
folate intake was not further explored in the study by Bautista et al.18
In a large case–case comparison of colorectal adenoma patients,7
individuals in the upper tertile of total folate intake (dietary and
supplemental folate), compared to individuals in the lowest tertile, had
a nearly 50% lower risk of having K-ras mutation-positive adenomas
(OR  0.52, 95% CI  0.30–0.88; ptrend  0.02). This reduction in
risk of K-ras mutation-positive adenomas was not observed for di-
etary folate intake alone (OR  0.91, 95% CI  0.50–1.64; ptrend 
0.75). Caution is warranted in interpreting these results, because
case–case comparisons, including both male and female colon and
rectal adenomas, were carried out. Case–case comparisons are valu-
able for the estimation of etiologic heterogeneity with regard to K-ras
mutation status. They do not, however, give information on the
direction of the association between folate and K-ras wild-type or
mutated tumors, respectively. This can only be obtained with case–
control comparisons. In addition, we observed distinct differences in
associations between men and women and colon and rectal cancer.
Our results do not support the protective effect of folate for mutated
K-ras colon tumors observed in the other studies. One explanation
could be that dietary folate intake in The Netherlands is too low to
evoke its potentially protective effect in colon and rectal cancer,
although a protective effect was observed for male rectal cancer. In
the NLCS, 22% of the study population used vitamin B supplements
in 1986.32 Due to legislative restrictions in The Netherlands, however,
it was not until 1994 that using folic acid in vitamin supplements was
allowed. The overall effect of folic acid supplements in this cohort is
presumably negligible.
In our current study, an inverse association was observed for
women between high folate intake and rectal tumors harboring a
GA transition in the K-ras oncogene. This was also observed for
both men and women by Slattery et al.17 although not statistically
signiﬁcant, for GA transitions at the second position of codon 12
(OR for lowest tertile vs. highest tertile of intake 0.7, 95% CI 
0.4–1.3; ptrend  0.11). This could be an indirect consequence of
promotor hypermethylation of mismatch repair genes like the
O6-methylguanine DNA methyltransferase (MGMT) gene. Van
Engeland et al.10 evaluated the association between promoter
hypermethylation of genes involved in colorectal carcinogenesis,
like MGMT, and folate and alcohol intake within the framework of
the NLCS. MGMT is a DNA repair protein that removes adducts
from the O6 position of guanine9 in DNA, thereby preventing
GA or CT mutations. Despite the limited size of the study
carried out by van Engeland et al.,10 the data suggest that low
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folate and high alcohol intakes may be associated with promoter
hypermethylation in genes involved in CRC (i.e., MGMT). No
clear associations were observed for folate and GA transitions in
men, neither in the colon nor the rectum. More etiological insight
in the underlying mechanisms relating the differences in tumor
site, gender and K-ras mutation status in colorectal cancer is
required to clarify this issue. Moreover, due to the overall small
number of cases when studying subgroups of K-ras mutated tu-
mors, the results of our study should be interpreted with caution,
and need replication in future larger studies.
We observed an increased risk of rectal cancer with increased
folate intake in women. This was observed for both wild-type and
mutated K-ras gene (i.e., GT and GC transversions) but not for
GA transitions as described above. For men, however, an inverse
association with GT and GC transversions in rectal tumors was
observed. Another recent study also showed elevated risks for
rectal cancer in women with increased dietary folate intake, though
not statistically signiﬁcant.4 With the folate food fortiﬁcations and
extensive use of (multi)vitamin supplements including folate in
different countries it is important to further investigate this issue in
prospective studies.
In conclusion, in our study dietary folate is not associated
signiﬁcantly with colon cancer risk, neither overall nor with the
K-ras mutation status. Our data suggest that the effect of folate on
rectal cancer risk is different for men and women and depends on
the K-ras mutation status of the tumor.
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TABLE III – INCIDENCE RR AND 95% CI FOR COLON CANCER PATIENTS OVERALL AND WITH A (SPECIFIC)
K-RAS MUTATION STATUS (N  448) ACCORDING TO DIETARY FOLATE INTAKE
Men Women
n RR (95% CI) n RR (95% CI)
Colon cancer
RRage 231 1.08 (0.91–1.30) 199 0.87 (0.67–1.15)
RRmultivariate1 231 0.87 (0.66–1.14) 199 0.98 (0.62–1.56)
Wild-type K-ras
RRmultivariate1 148 0.94 (0.69–1.27) 141 0.89 (0.52–1.52)
Mutated K-ras
RRmultivariate1 83 0.76 (0.47–1.22) 58 1.22 (0.52–2.82)
GA transition
RRmultivariate1 47 0.78 (0.40–1.53) 34 1.29 (0.48–3.49)
GT, GC transversions
RRmultivariate1 29 0.77 (0.41–1.45) 25 1.56 (0.49–4.95)
1RR adjusted for age, BMI, smoking, alcohol, fresh meat, energy intake and family history of CRC, vitamin C, iron, ﬁbre. RR per increment
of 100 g/day increase of dietary folate intake.
TABLE IV – INCIDENCE RR AND 95% CI FOR RECTAL CANCER PATIENTS OVERALL AND WITH A (SPECIFIC)
K-RAS MUTATION STATUS (N  160) ACCORDING TO DIETARY FOLATE INTAKE
Men Women
n RR (95% CI) n RR (95% CI)
Rectal cancer
RRage 99 0.89 (0.68–1.16) 51 1.43 (0.98–2.08)
RRmultivariate1 99 0.58 (0.36–0.93) 51 1.85 (1.13–3.02)
Wild-type K-ras
RRmultivariate1 63 0.69 (0.40–1.19) 24 1.94 (1.03–3.66)
Mutated K-ras
RRmultivariate1 36 0.40 (0.17–0.89) 27 1.83 (0.91–3.68)
GA transition
RRmultivariate1 22 0.68 (0.36–1.28) 11 0.08 (0.01–0.53)
GT, GC transversions
RRmultivariate1 13 0.19 (0.03–1.07) 17 2.69 (1.43–5.09)
1RR adjusted for age, BMI, smoking, alcohol, fresh meat, energy intake and family history of CRC, vitamin C, iron, ﬁbre. RR per increment
of 100 g/day increase of dietary folate intake.
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